Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort studyMarie Kostine, Thierry Schaeverbeke, Nadia Mehsen et al.|Annals of the Rheumatic Diseases|2017Cited by 302
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse eventsMarie Kostine, Thierry Schaeverbeke, Eleonora Mauric et al.|European Journal of Cancer|2021Cited by 93
Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysisCéline Eldani, E. Gérard, Marie Kostine et al.|Frontiers in Oncology|2024Cited by 14
Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational studyAlexandra Ladouceur, Marie Kostine, Thomas Barnetche et al.|RMD Open|2023Cited by 9
Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational studyAlexandra Ladouceur, Marie Kostine, Thomas Barnetche et al.|Joint Bone Spine|2024Cited by 5